KRAS G12C
|
Ampulla of Vater Carcinoma
|
KRAS G12C
|
Ampulla of Vater Carcinoma
|
sotorasib Sensitive: C1 - Off-label
|
sotorasib Sensitive: C1 - Off-label
|
MUC2 negative
|
Ampulla of Vater Carcinoma
|
MUC2 negative
|
Ampulla of Vater Carcinoma
|
gemcitabine Resistant: C3 – Early Trials
|
gemcitabine Resistant: C3 – Early Trials
|
KRT7 expression
|
Ampulla of Vater Carcinoma
|
KRT7 expression
|
Ampulla of Vater Carcinoma
|
gemcitabine Resistant: C3 – Early Trials
|
gemcitabine Resistant: C3 – Early Trials
|
KRT7 expression
|
Ampulla of Vater Carcinoma
|
KRT7 expression
|
Ampulla of Vater Carcinoma
|
cisplatin + gemcitabine + albumin-bound paclitaxel Sensitive: C3 – Early Trials
|
cisplatin + gemcitabine + albumin-bound paclitaxel Sensitive: C3 – Early Trials
|
KRT7 expression + MUC1 expression
|
Ampulla of Vater Carcinoma
|
KRT7 expression + MUC1 expression
|
Ampulla of Vater Carcinoma
|
gemcitabine + albumin-bound paclitaxel Sensitive: C3 – Early Trials
|
gemcitabine + albumin-bound paclitaxel Sensitive: C3 – Early Trials
|
HER-2 mutation + CDK6 mutation
|
Ampulla of Vater Carcinoma
|
HER-2 mutation + CDK6 mutation
|
Ampulla of Vater Carcinoma
|
palbociclib + pertuzumab + abemaciclib + ribociclib + trastuzumab/hyaluronidase-oysk Sensitive: C3 – Early Trials
|
palbociclib + pertuzumab + abemaciclib + ribociclib + trastuzumab / hyaluronidase-oysk Sensitive: C3 – Early Trials
|
BRAF D594G
|
Ampulla of Vater Carcinoma
|
BRAF D594G
|
Ampulla of Vater Carcinoma
|
encorafenib + binimetinib Sensitive: C3 – Early Trials
|
encorafenib + binimetinib Sensitive: C3 – Early Trials
|
PIK3CA mutation
|
Ampulla of Vater Carcinoma
|
PIK3CA mutation
|
Ampulla of Vater Carcinoma
|
everolimus Sensitive: C4 – Case Studies
|
everolimus Sensitive: C4 – Case Studies
|
NRAS mutation + BRAF mutation
|
Ampulla of Vater Carcinoma
|
NRAS mutation + BRAF mutation
|
Ampulla of Vater Carcinoma
|
MEK inhibitor Sensitive: C4 – Case Studies
|
MEK inhibitor Sensitive: C4 – Case Studies
|
HER-2 G660D + HER-2 S310F
|
Ampulla of Vater Carcinoma
|
HER-2 G660D + HER-2 S310F
|
Ampulla of Vater Carcinoma
|
afatinib Sensitive: C4 – Case Studies
|
afatinib Sensitive: C4 – Case Studies
|